Faricimab Increases Fluid-Free Interval, Extends Dosing Interval in Patients With AMD
December 12th 2023Patients with age-related macular degeneration (AMD) who were not responsive to anti–vascular endothelial growth factor agents were able to increase their fluid-free intervals with faricimab.
Read More
Pivotal Results Show Revumenib Holds Promise for Patients With KMT2Ar Acute Leukemia
December 12th 2023In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
Read More
Frontline Daratumumab Plus VRd Outperforms Standard VRd Alone in Multiple Myeloma
December 12th 2023A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.
Read More
Metformin Does Not Improve Neonatal Outcomes for Pregnant Patients With Diabetes
December 12th 2023Adding metformin to the insulin regimen for pregnant patients with preexisting type 2 diabetes (T2D) or gestational diabetes diagnosed early in pregnancy did not reduce the risk of neonatal adverse outcomes.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More
Eye Changes After Cataract Surgery Associated With Diabetic Retinopathy
December 11th 2023Patients receiving uncomplicated phacoemulsification surgery for cataracts had greater increases in macular and choroidal thickness if they had early diabetic retinopathy without preoperative diabetic macular edema.
Read More
Short Sleep Duration Linked With All-Cause Mortality in Patients With Sleep Apnea
December 11th 2023New results from the Sleep Heart Health Study (SHHS) identified a significant association between sleep duration and all-cause mortality among individuals grappling with obstructive sleep apnea (OSA).
Read More
Second-Line Axi-Cel Prolongs Survival Over Standard of Care in Elderly Patients With R/R LBCL
December 11th 2023The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.
Read More
ICYMI: Highlights From the ACCC Fall National Oncology Conference
December 11th 2023This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.
Read More
Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So
December 11th 2023Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.
Read More
FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease
December 10th 2023The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.
Read More
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
December 10th 2023Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Read More